Please check your internet connection and try again.
# Lennox-Gastaut Syndrome (LGS)
## Overview
Lennox-Gastaut Syndrome is a severe form of childhood-onset epilepsy characterized by multiple seizure types (tonic, atonic, absence), slow spike-wave patterns on EEG, and intellectual impairment. Management is typically polytherapeutic and frequently refractory to treatment.
## Primary Indications
Adjunctive therapy for seizures associated with LGS. Common agents include Clobazam, Rufinamide, Topiramate, Lamotrigine, Cannabidiol (CBD), and Felbamate. Fenfluramine is also utilized.
## Adult Dosing
* **Clobazam:** Start 5-10 mg/day; titrate weekly to 20 mg/day. Max 40 mg/day.
* **Rufinamide:** Start 400-800 mg/day in two divided doses; titrate by 400-800 mg every 2 days. Max 3200 mg/day (or 45 mg/kg/day).
* **Cannabidiol:** 2.5 mg/kg twice daily (5 mg/kg/day); may increase to 10 mg/kg twice daily (20 mg/kg/day) after 1 week.
## Pediatric Dosing
* **Clobazam (≥2 years):** Weight-based: <30 kg: Start 5 mg/day, max 20 mg/day. ≥30 kg: Start 10 mg/day, max 40 mg/day.
* **Rufinamide (≥1 year):** Start ~10 mg/kg/day divided BID; titrate up to 45 mg/kg/day (max 3200 mg/day).
* **Cannabidiol (≥1 year):** Same as adult dosing (titrate to 20 mg/kg/day).
* **Topiramate (dosing varies widely):** Usually 5–9 mg/kg/day in two divided doses.
*Note: Dosing depends heavily on concurrent medications (e.g., Valproic acid increases Clobazam/Rufinamide levels significantly). Clinical protocols vary; consult institution-specific epilepsy guidelines.*
## Dose Adjustments
* **Hepatic/Renal:** Significant adjustments required for most agents. Example: Rufinamide is contraindicated in severe hepatic impairment; adjust dosing in renal failure.
* **Drug-Drug Interactions:** Valproic acid often necessitates dose reductions for many LGS medications (especially Clobazam and Rufinamide) to avoid toxicity.
## Contraindications
* **General:** Known hypersensitivity to the drug or excipients.
* **Rufinamide:** Short QT syndrome.
* **Clobazam:** Myasthenia gravis, severe respiratory insufficiency.
* **Felbamate:** History of hepatic failure or bone marrow depression.
## Adverse Effects
* **Common:** Somnolence, fatigue, dizziness, gastrointestinal distress, ataxia, and weight loss/appetite reduction (common with Topiramate/Cannabidiol).
* **Serious:** Suicidal ideation (all AEDs), SJS/TEN (Lamotrigine), hepatotoxicity (Felbamate, Cannabidiol), and aplastic anemia (Felbamate).
## Key Drug Interactions
* **Valproic Acid:** Potent inhibitor of metabolism; significantly increases serum concentrations of Clobazam (active metabolite N-desmethylclobazam) and Rufinamide.
* **CYP450 Inducers:** Carbamazepine, Phenytoin, and Phenobarbital can decrease levels of many LGS medications (e.g., Rufinamide, Clobazam, Topiramate).
## Monitoring
* **Hematologic:** CBC (if on Felbamate).
* **Hepatic:** ALT, AST, and total bilirubin (especially with Cannabidiol or Felbamate).
* **Neurologic:** Seizure frequency charts, lethargy/sedation assessments.
* **Cardiac:** ECG monitoring (specifically for QTc prolongation with Rufinamide).
## Clinical Pearls
1. **"Start low, go slow":** Pediatric patients are highly sensitive; titrating too quickly increases side effects and reduces compliance.
2. **Valproate Concomitant Use:** Always check for Valproate use when initiating Clobazam or Rufinamide; the interaction is clinically significant.
3. **Refractory Nature:** LGS is rarely controlled by a single agent; focus is on balancing seizure reduction with neurocognitive side effects.
4. **Rescue Medications:** Ensure caregiver has a plan for status epilepticus (e.g., buccal midazolam or rectal diazepam).
***
**Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always verify dosages, contraindications, and drug-drug interactions through current, institution-specific protocols or reputable clinical databases (e.g., Lexicomp, Micromedex) before prescribing.
